Evaluation of the clinical implementation of biofilm susceptibility to antibiotics using Minimum Biofilm Eradication Concentration (MBEC) in addition to Minimum Inhibitory Concentration (MIC) to guide the treatment of periprosthetic joint infections; a prospective randomized clinical trial

Conditions

Periprosthetic hip joint infection Periprosthetic knee joint infection

Brief summary

Proportions of antimicrobial regimens other than 1st-line treatment that will be administered after the guidance of MIC-testing versus MIC- and MBEC-testing combined. [6 weeks]

Detailed description

Repeat procedure, relapse or reinfection [12 months], Oxford Hip Score/Oxford Knee Score [12 months], EQ-5D: Generic health status patient-reported outcome measure [12 months], Time to revision [12 months], Inpatient care: Resource consumption measure (days) [Up to 12 months], Outpatient visits: Resource consumption measure, number of visits, type of visits [Up to 12 months], Discharge destination: Resource consumption measure [Up to 12 months], Heath care costs: Compound measure using data from outcome 6-8 (currency EUR) [Time Frame: Up to 12 months], Development of additional antimicrobial resistance of the relapse causative strain [12 months], Correlation between the virulence properties of the causative bacteria and patient outcome (infection resolution versus recurrent infection) [12 months]

Related papers

No related papers found yet.

Papers published before 2008-02-04 may not appear yet. Historical indexing is in progress.

Interventions

DRUGLINEZOLID

DRUGFUSIDIC ACID

DRUGRIFAMPICIN

DRUGLEVOFLOXACIN

DRUGSULFAMETHOXAZOLE AND TRIMETHOPRIM

DRUGCLINDAMYCIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Proportions of antimicrobial regimens other than 1st-line treatment that will be administered after the guidance of MIC-testing versus MIC- and MBEC-testing combined. [6 weeks]	—

Secondary

Measure	Time frame
Repeat procedure, relapse or reinfection [12 months], Oxford Hip Score/Oxford Knee Score [12 months], EQ-5D: Generic health status patient-reported outcome measure [12 months], Time to revision [12 months], Inpatient care: Resource consumption measure (days) [Up to 12 months], Outpatient visits: Resource consumption measure, number of visits, type of visits [Up to 12 months], Discharge destination: Resource consumption measure [Up to 12 months], Heath care costs: Compound measure using data from outcome 6-8 (currency EUR) [Time Frame: Up to 12 months], Development of additional antimicrobial resistance of the relapse causative strain [12 months], Correlation between the virulence properties of the causative bacteria and patient outcome (infection resolution versus recurrent infection) [12 months]	—

Measure

Time frame

Repeat procedure, relapse or reinfection [12 months], Oxford Hip Score/Oxford Knee Score [12 months], EQ-5D: Generic health status patient-reported outcome measure [12 months], Time to revision [12 months], Inpatient care: Resource consumption measure (days) [Up to 12 months], Outpatient visits: Resource consumption measure, number of visits, type of visits [Up to 12 months], Discharge destination: Resource consumption measure [Up to 12 months], Heath care costs: Compound measure using data from outcome 6-8 (currency EUR) [Time Frame: Up to 12 months], Development of additional antimicrobial resistance of the relapse causative strain [12 months], Correlation between the virulence properties of the causative bacteria and patient outcome (infection resolution versus recurrent infection) [12 months]

—

Countries

Sweden

Outcome results

None listed